Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease

Paediatric Anaesthesia

Volumn 23, Issue 8, 2013, Pages 684-689

  Neri, Caitlin M ^a,b   Pestieau, Sophie R ^a,b   Darbari, Deepika S ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

analgesics; anemia; hyperalgesia; ketamine; opioid; pain; sickle cell drug therapy; tolerance

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADJUVANT THERAPY; ANALGESIA; CANCER PAIN; CARDIOVASCULAR RESPONSE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; INOTROPISM; LOW DRUG DOSE; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SICKLE CELL CRISIS;

ANALGESICS; ANEMIA; HYPERALGESIA; KETAMINE; OPIOID; PAIN; SICKLE CELL/DRUG THERAPY; TOLERANCE;

ANEMIA, SICKLE CELL; ANESTHETICS, DISSOCIATIVE; ARTERIAL OCCLUSIVE DISEASES; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; PAIN; PAIN, INTRACTABLE;

EID: 84879888273     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12172     Document Type: Review

References (86)

1. Shapiro BS, Ballas SK,. The acute painful episode. In:, Embury SH, Hebbel RP, Mohandas N, Steinberg M, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY: Raven Press, 1994: 531-543.
2. Steiner CA, Miller JL,. Sickle Cell Disease Patients in U.S. Hospitals, 2004: Statistical Brief #21. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Heathcare Research and Quality, 2006.
3. Oliver-Carpenter G, Barach I, Crosby LE, et al,. Disease management, coping, and functional disability in pediatric sickle cell disease. J Natl Med Assoc 2011; 103: 131-137.
4. Palermo TM, Riley CA, Mitchell BA,. Daily functioning and quality of life in children with sickle cell disease pain: relationship with family and neighborhood socioeconomic distress. J Pain 2008; 9: 833-840.
5. Benjamin L, Dampier C, Jacox A, et al,. Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. APS Clinical Practice Guidelines Series, No. 1 ed. Glenview, IL: American Pain Society, 1999.
6. Platt OS, Thorington BD, Brambilla DJ, et al,. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325: 11-16.
7. Platt OS, Brambilla DJ, Rosse WF, et al,. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
8. Dunlop RJ, Bennett KC,. Pain management for sickle cell disease. Cochrane Database Syst Rev 2006; CD003350.
9. Ballas SK,. Update on pain management in sickle cell disease. Hemoglobin 2011; 35: 520-529.
10. Smith WR, Scherer M,. Sickle-cell pain: advances in epidemiology and etiology. Hematology Am Soc Hematol Educ Program 2010; 2010: 409-415.
11. Jacob E, Miaskowski C, Savedra M, et al,. Quantification of analgesic use in children with sickle cell disease. Clin J Pain 2007; 23: 8-14.
12. Jacob E, Mueller BU,. Pain experience of children with sickle cell disease who had prolonged hospitalizations for acute painful episodes. Pain Med 2008; 9: 13-21.
13. Koppert W, Sittl R, Scheuber K, et al,. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003; 99: 152-159.
14. Collett BJ,. Opioid tolerance: the clinical perspective. Br J Anaesth 1998; 81: 58-68.
15. Freye E, Latasch L,. Development of opioid tolerance-molecular mechanisms and clinical consequences. Anasthesiol Intensivmed Notfallmed Schmerzther 2003; 38: 14-26.
16. Aley KO, Green PG, Levine JD,. Opioid and adenosine peripheral antinociception are subject to tolerance and withdrawal. J Neurosci 1995; 15: 8031-8038.
17. Aley KO, Levine JD,. Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. J Neurosci 1997; 17: 735-744.
18. Aley KO, Levine JD,. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. J Neurosci 1997; 17: 8018-8023.
19. Khasar SG, Wang JF, Taiwo YO, et al,. Mu-opioid agonist enhancement of prostaglandin-induced hyperalgesia in the rat: a G-protein beta gamma subunit-mediated effect? Neuroscience 1995; 67: 189-195.
20. Mao J, Sung B, Ji RR, et al,. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22: 8312-8323.
21. Wong CS, Wu GJ, Chen WF, et al,. N-Methyl- d -aspartate receptor antagonist d-AP5 prevents pertussis toxin-induced alterations in rat spinal cords by inhibiting increase in concentrations of spinal CSF excitatory amino acids and downregulation of glutamate transporters. Brain Res Bull 2009; 80: 69-74.
22. Kayser V, Besson JM, Guilbaud G,. Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). Brain Res 1987; 414: 155-157.
23. Kissin I, Bright CA, Bradley EL Jr,. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg 2000; 91: 1483-1488.
24. Larcher A, Laulin JP, Celerier E, et al,. Acute tolerance associated with a single opiate administration: involvement of N-methyl- d -aspartate-dependent pain facilitatory systems. Neuroscience 1998; 84: 583-589.
25. Crain SM, Shen KF,. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000; 84: 121-131.
26. Crain SM, Shen KF,. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem Res 1996; 21: 1347-1351.
27. Avidor-Reiss T, Bayewitch M, Levy R, et al,. Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem 1995; 270: 29732-29738.
28. Suresh S, Anand KJ,. Opioid tolerance in neonates: mechanisms, diagnosis, assessment, and management. Semin Perinatol 1998; 22: 425-433.
29. Mayer DJ, Mao J, Holt J, et al,. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 1999; 96: 7731-7736.
30. Crain SM, Shen KF,. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA 1995; 92: 10540-10544.
31. King T, Ossipov MH, Vanderah TW, et al,. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid tolerance? Neurosignals 2005; 14: 194-205.
32. Chu LF, Angst MS, Clark D,. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24: 479-496.
33. Angst MS, Clark JD,. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104: 570-587.
34. Crain SM, Shen KF,. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 2001; 888: 75-82.
35. Narita M, Mizoguchi H, Narita M, et al,. Involvement of spinal protein kinase C gamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2, N-MePhe4, Gly-Ol(5)]enkephalin. J Neurosci 2001; 21: 3715-3720.
36. Mao J,. NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Brain Res Rev 1999; 30: 289-304.
37. Vanderah TW, Gardell LR, Burgess SE, et al,. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074-7079.
38. Gardell LR, Wang R, Burgess SE, et al,. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22: 6747-6755.
39. Wong CS, Hsu MM, Chou R, et al,. Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. Br J Anaesth 2000; 85: 747-751.
40. Doverty M, Somogyi AA, White JM, et al,. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001; 93: 155-163.
41. Doverty M, White JM, Somogyi AA, et al,. Hyperalgesic responses in methadone maintenance patients. Pain 2001; 90: 91-96.
42. Compton MA,. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage 1994; 9: 462-473.
43. Compton P, Canamar CP, Hillhouse M, et al,. Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. J Pain 2012; 13: 401-409.
44. Compton P, Charuvastra VC, Kintaudi K, et al,. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage 2000; 20: 237-245.
45. Compton P, Charuvastra VC, Ling W,. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63: 139-146.
46. Compton P, Kehoe P, Sinha K, et al,. Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend 2010; 109: 213-219.
47. Lotsch J, Skarke C, Grosch S, et al,. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9.
48. Trujillo KA, Akil H,. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85-87.
49. Marek P, Ben-Eliyahu S, Gold M, et al,. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 1991; 547: 77-81.
50. Li X, Angst MS, Clark JD,. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res 2001; 86: 56-62.
51. Haugan F, Rygh LJ, Tjolsen A,. Ketamine blocks enhancement of spinal long-term potentiation in chronic opioid treated rats. Acta Anaesthesiol Scand 2008; 52: 681-687.
52. De Kock M, Lavand'homme P, Waterloos H,. 'Balanced analgesia' in the perioperative period: is there a place for ketamine? Pain 2001; 92: 373-380.
53. Elia N, Tramer MR,. Ketamine and postoperative pain-a quantitative systematic review of randomised trials. Pain 2005; 113: 61-70.
54. Fine PG,. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999; 17: 296-300.
55. Finkel JC, Pestieau SR, Quezado ZM,. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain 2007; 8: 515-521.
56. Menigaux C, Fletcher D, Dupont X, et al,. The benefits of intraoperative small-dose ketamine on postoperative pain after anterior cruciate ligament repair. Anesth Analg 2000; 90: 129-135.
57. Bell RF, Eccleston C, Kalso E,. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage 2003; 26: 867-875.
58. Bergman SA,. Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999; 46: 10-20.
59. Lin C, Durieux ME,. Ketamine and kids: an update. Pediatr Anesth 2005; 15: 91-97.
60. Dahmani S, Michelet D, Abback PS, et al,. Ketamine for perioperative pain management in children: a meta-analysis of published studies. Pediatr Anesth 2011; 21: 636-652.
61. Fu ES, Miguel R, Scharf JE,. Preemptive ketamine decreases postoperative narcotic requirements in patients undergoing abdominal surgery. Anesth Analg 1997; 84: 1086-1090.
62. Hagelin A, Lundberg D,. Ketamine for postoperative analgesia after upper abdominal surgery. Clin Ther 1981; 4: 229-233.
63. Himmelseher S, Durieux ME,. Ketamine for perioperative pain management. Anesthesiology 2005; 102: 211-220.
64. Jahangir SM, Islam F, Aziz L,. Ketamine infusion for postoperative analgesia in asthmatics: a comparison with intermittent meperidine. Anesth Analg 1993; 76: 45-49.
65. Krystal JH, Karper LP, Seibyl JP, et al,. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
66. Roytblat L, Korotkoruchko A, Katz J, et al,. Postoperative pain: the effect of low-dose ketamine in addition to general anesthesia. Anesth Analg 1993; 77: 1161-1165.
67. Saegusa K, Furukawa Y, Ogiwara Y, et al,. Pharmacologic analysis of ketamine-induced cardiac actions in isolated, blood-perfused canine atria. J Cardiovasc Pharmacol 1986; 8: 414-419.
68. Reich DL, Silvay G,. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989; 36: 186-197.
69. Kye YC, Rhee JE, Kim K, et al,. Clinical effects of adjunctive atropine during ketamine sedation in pediatric emergency patients. Am J Emerg Med 2012; 30: 1981-1985.
70. Sun L, Li Q, Li Q, et al,. Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys. Addict Biol 2012; [Epub ahead of print].
71. Liu F, Patterson TA, Sadovova N, et al,. Ketamine induced neuronal damage and altered N-methyl- d -aspartate (NMDA) receptor function in rat primary forebrain culture. Toxicol Sci 2012; [Epub ahead of print].
72. Brambrink AM, Evers AS, Avidan MS, et al,. Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain. Anesthesiology 2012; 116: 372-384.
73. Burburan SM, Xisto DG, Rocco PR,. Anaesthetic management in asthma. Minerva Anestesiol 2007; 73: 357-365.
74. Krystal JH, Karper LP, Bennett A, et al,. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998; 135: 213-229.
75. Sadove MS, Shulman M, Hatano S, et al,. Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg 1971; 50: 452-457.
76. Joachimsson PO, Hedstrand U, Eklund A,. Low-dose ketamine infusion for analgesia during postoperative ventilator treatment. Acta Anaesthesiol Scand 1986; 30: 697-702.
77. Goyal R, Singh M, Sharma J,. Comparison of ketamine with fentanyl as co-induction in propofol anesthesia for short surgical procedures. Int J Crit Illn Inj Sci 2012; 2: 17-20.
78. Elshammaa N, Chidambaran V, Housny W, et al,. Ketamine as an adjunct to fentanyl improves postoperative analgesia and hastens discharge in children following tonsillectomy-a prospective, double-blinded, randomized study. Pediatr Anesth 2011; 21: 1009-1014.
79. Bell RF, Dahl JB, Moore RA, et al,. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; CD004603.
80. Subramaniam K, Subramaniam B, Steinbrook RA,. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99: 482-495, table of contents.
81. Conway M, White N, Jean CS, et al,. Use of continuous intravenous ketamine for end-stage cancer pain in children. J Pediatr Oncol Nurs 2009; 26: 100-106.
82. James PJ, Howard RF, Williams DG,. The addition of ketamine to a morphine nurse- or patient-controlled analgesia infusion (PCA/NCA) increases analgesic efficacy in children with mucositis pain. Pediatr Anesth 2010; 20: 805-811.
83. Zempsky WT, Loiselle KA, Corsi JM, et al,. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain 2010; 26: 163-167.
84. Meals CG, Mullican BD, Shaffer CM, et al,. Ketamine infusion for sickle cell crisis pain in an adult. J Pain Symptom Manage 2011; 42: e7-e9.
85. Niesters M, Dahan A,. Pharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain. Expert Opin Drug Metab Toxicol 2012; 8: 1409-1417.
86. Cha MH, Eom JH, Lee YS, et al,. Beneficial effects of adding ketamine to intravenous patient-controlled analgesia with fentanyl after the Nuss procedure in pediatric patients. Yonsei Med J 2012; 53: 427-432.